Sarepta price target raised to $186 from $176 at BofA

BofA raised the firm’s price target on Sarepta to $186 from $176 and keeps a Buy rating on the shares after the company announced the approval of SRP-9001, now called Elevidys, for ambulatory DMD patients ages 4-5. The firm, which is updating its assumptions but sees “more room for upside,” views the approval and initial age-restricted label as in-line with expectations and reiterates its view that the initial age-restricted label does not impact its estimates.